Tumor type: Transitional Cell Carcinoma
Purpose of Study: The goal of this study is to assess efficacy of Palladia and Vinblastine combined for treatment of canine transitional cell carcinoma and to compare computerized tomography and ultrasound for measurement of tumor response.
The two drugs to be combined in this clinical trial are vinblastine, a chemotherapy agent used to treat several different cancers in dogs, and Palladia, an oral drug that works by blocking the signaling of several receptors, including VEGFR2 and PDGFR. Both VEGFR2 and PDGFR are important in permitting the growth of new blood vessels, so Palladia works to slow down or block the growth a blood supply into tumors and prevent them from continuing to grow. There is preliminary evidence that both vinblastine and Palladia may each have some activity against TCC in dogs. A recent pilot study demonstrated that 36% of dogs with TCC given vinblastine had their tumor shrink partially following treatment and another 50% had their tumors stop growing for a period of time. In previous work with Palladia, 3 of 4 dogs treated with drug had their tumors stop growing for a period of time. Vinblastine and Palladia have recently been combined together in a clinical trial to determine how best to use these drugs together in the setting of mast cell cancer. This study identified the dose of vinblastine and Palladia that could be safely combined over multiple treatments. These doses will be used in the current study. For more information, click here.